ALE.F02

BIOLOGICAL2 trials

Sponsors

Alentis Therapeutics AG

Conditions

Advanced Liver FibrosisGlomerulonephritis Rapidly ProgressiveLiver Cirrhosis

Phase 1

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

CompletedNCT05939947

Alentis Therapeutics AGAdvanced Liver Fibrosis, Liver Cirrhosis

Start: 2023-04-01End: 2024-10-30Updated: 2024-12-03

Phase 2

Rescue of Nephrons With ALE.F02 (RENAL-F02)

RecruitingNCT06047171

Alentis Therapeutics AGGlomerulonephritis Rapidly Progressive

Start: 2023-09-07End: 2028-02-28Target: 80Updated: 2026-08-14

Related Papers

#2837 Novel therapeutic for crescentic glomerulonephritis through targeting CLDN1 in parietal epithelial cells

Nephrology Dialysis Transplantation2024-05-012 citations